2. Search Result
Search Result
Results for "

Wistar rat

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

4

Biochemical Assay Reagents

7

Peptides

18

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-126389
    Chitin, from crab carapace (powder),biomedical research grade

    		Environmental Pollutants Endogenous Metabolite Fungal NF-κB Biochemical Assay Reagents Infection Inflammation/Immunology
    Chitin, from crab carapace (powder),biomedical research grade is a long-chain polymer of N-acetylglucosamine with β-(1-4) linkages. Chitin, from crab carapace (powder),biomedical research grade is found in the exoskeleton of crabs. Chitin, from crab carapace (powder),biomedical research grade inhibits the activation of NF-κB p65, alters the translocation of NF-κB p65 to the nucleus, and interacts with the cell wall of Candida species. Chitin, from crab carapace (powder),biomedical research grade exerts antifungal and anti-inflammatory effects. Chitin, from crab carapace (powder),biomedical research grade can be used in the research of gastric ulcer and candidiasis .
    Chitin, from crab carapace (powder),biomedical research grade
  • HY-P1944
    Apelin-13
    5+ Cited Publications

    		 Apelin Receptor (APJ) Cardiovascular Disease Metabolic Disease
    Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
    Apelin-13
  • HY-P1944A
    Apelin-13 TFA
    5+ Cited Publications

    		 Apelin Receptor (APJ) Cardiovascular Disease Metabolic Disease
    Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome .
    Apelin-13 TFA
  • HY-Y0399
    L-Norvaline

    Norvaline

    		 Amyloid-β TNF Receptor Arginase Neurological Disease Metabolic Disease
    L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .
    L-Norvaline
  • HY-105174A
    BPC 157 acetate

    		JAK FAK Neurological Disease Metabolic Disease
    BPC 157 acetate is an orally active peptide. BPC 157 acetate exhibits multiple activities such as promoting wound healing, tendon healing, neuroprotection, and gastrointestinal protection. BPC 157 acetate can be used in the research of tendon injury, burn, gastric ulcer, and neurological diseases .
    BPC 157 acetate
  • HY-W011848
    Monobenzyl phthalate

    2-((Benzyloxy)carbonyl)benzoic acid

    		 Drug Metabolite Metabolic Disease
    Monobenzyl phthalate is a phthalate metabolite (aromatic alkyl chain monophthalate) with oral activity, which acts as a male reproductive development inhibitor and antiandrogen in rat fetuses .
    Monobenzyl phthalate
  • HY-N0886
    Aloin B
    3 Publications Verification

    Isobarbaloin

    		 SARS-CoV Virus Protease Infection Endocrinology Cancer
    Aloin B (Isobarbaloin) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 16.08 μM (hydrolytic activity) and 17.51 μM (deubiquitinase activity). Aloin B is metabolized by rat intestinal flora into aloe-emodin-9-anthrone to exert laxative effects. Aloin B inhibits TPA (HY-18739)-induced ear edema, putrescine elevation, and tumor promotion in mouse skin. Aloin B can be used in research related to anti-inflammation, tumor promotion inhibition, coronavirus disease 2019 (COVID-19) and constipation .
    Aloin B
  • HY-113256
    Linoleyl carnitine

    		Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite Metabolic Disease
    Linoleyl carnitine is an acylcarnitine and metabolite. Linoleyl carnitine in the liver is negatively correlated with pantothenic acid and citric acid in serum. Linoleyl carnitine accumulates in mitochondrial CPT II deficiency .
    Linoleyl carnitine
  • HY-105088
    Pexiganan

    MSI 78 free base

    		 Bacterial Infection Cancer
    Pexiganan (MSI 78) is an orally active antimicrobial peptide with broad-spectrum bactericidal. Pexiganan disrupts bacterial cell membranes, induces peptidoglycan damage and cell lysis. Pexiganan TFA can be used for the research of bacterial infection .
    Pexiganan
  • HY-W042193
    2-Piperidone

    δ-Valerolactam

    		 Endogenous Metabolite Metabolic Disease
    2-Piperidone is an endogenous metabolite. 2-Piperidone is the biomarker for the activity of CYP2E1 .
    2-Piperidone
  • HY-B1014
    Acenocoumarol

    		VD/VDR p38 MAPK JNK ERK NF-κB Akt GSK-3 PKA Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase .
    Acenocoumarol
  • HY-B2235C
    L-α-Lecithin (soybean)

    		Biochemical Assay Reagents Glutathione Peroxidase Metabolic Disease
    L-α-Lecithin (soybean) is an orally active phospholipid. L-α-Lecithin (soybean) increases the bioavailability of Lutein in plasma and eyes of Rattus norvegicus, enhances plasma Glutathione peroxidase activity, and regulates fatty acids in plasma and tissues .
    L-α-Lecithin (soybean)
  • HY-114557
    NSC 90469

    3,5-Diiodo-L-thyronine

    		 JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen Metabolic Disease Inflammation/Immunology Endocrinology
    NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
    NSC 90469
  • HY-103151
    CP94253 hydrochloride

    		5-HT Receptor Neurological Disease Metabolic Disease
    CP94253 hydrochloride is an orally active, brain-penetrant and selective 5-HT1B receptor agonist with an Ki of 2 nM. CP94253 hydrochloride induces antidepressant-like effects, waking enhancement, sleep inhibition, increased sleep latency, hyperlocomotion, and suppressed aggressive behavior. CP94253 hydrochloride can be used for the research of depression and heightened aggressive behavior .
    CP94253 hydrochloride
  • HY-W013851
    EDTA-OH

    		Environmental Pollutants Biochemical Assay Reagents Others
    EDTA-OH is a chelating agent, which forms thermodynamically stable chelates with metal ions like calcium, magnesium, iron, zinc and copper . EDTA-OH exhibits ability of phytoremediation in heavy-metal-contaminated soils . EDTA-OH is able to cross brain-blood barrier .
    EDTA-OH
  • HY-136704
    GLS1 Inhibitor-1

    		Glutaminase Cancer
    GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC50 of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC50 of 0.3 nM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI50 of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics .
    GLS1 Inhibitor-1
  • HY-N2511
    Trimyristin

    		Cholinesterase (ChE) Phosphatase Infection Neurological Disease
    Trimyristin is an orally active compound. Trimyristin can be isolated from the seeds of nutmeg (Myristica fragrans). Trimyristin inhibits the activities of acetylcholinesterase (AChE), ACP and ALP, with IC50 values of 0.11, 0.16 and 0.18 mM, respectively. Trimyristin exerts competitive-noncompetitive inhibition on acetylcholinesterase, uncompetitive inhibition on ACP, and competitive/noncompetitive inhibition on ALP. Trimyristin restores the downregulated acetylcholinesterase concentration in the cerebral cortex of rats exposed to sodium arsenite. Trimyristin can be used in studies related to fascioliasis and neurotoxicity .
    Trimyristin
  • HY-107581
    MK-1903
    1 Publications Verification

    		 GPR109A MMP Metabolic Disease Inflammation/Immunology
    MK-1903 is an orally active full agonist of GPR109a/HCAR2, with an EC50 of 12.9 nM. MK-1903 activates antilipolytic and vasodilatory pathways, reduces plasma free fatty acid levels, and induces skin flushing. MK-1903 stimulates the expression of HCAR2 protein and regulates the inflammatory response of microglia. MK-1903 prevents the enhanced firing activity of spinal nociceptive neurons. MK-1903 triggers the release of MMP-9 and the formation of NET. MK-1903 can be used in the research of dyslipidemia and neuroinflammation-based central nervous system diseases .
    MK-1903
  • HY-P4371
    Hel 13-5

    		Biochemical Assay Reagents Inflammation/Immunology
    Hel 13-5 is a monomeric, lipophilic, basic amphipathic α-helical synthetic peptide composed of 18 amino acid residues. Hel 13-5 is designed as a substitute for proteins in artificial pulmonary surfactants, and it mimics the interaction between the N-terminal fragment of human pulmonary surfactant protein B and lipids. Hel 13-5 can bind to phospholipids for the development of pulmonary surfactant model systems. Hel 13-5 can be used in studies related to respiratory distress syndrome .
    Hel 13-5
  • HY-168366
    R-6890

    		Opioid Receptor Neurological Disease
    R-6890 is a Brorphine-related opioid receptor antagonist that exhibits differential binding activities toward rat opioid receptors (IC50=4.6 nM (0.05 M Tris; pH 7.4) and 170 nM (0.05 M Tris+0.1 M NaCl)). R-6890 displaces bound labeled opioids from receptors, and its binding affinity is affected by environmental factors, decreasing in the presence of NaCl. R-6890 crosses the blood-brain barrier (BBB) and exerts analgesic effects in the warm water-induced tail-flick reflex model of male Wistar rats .
    R-6890
  • HY-N7697F
    Chitobiose

    		Others Metabolic Disease
    Chitobiose is an orally active chitosan oligosaccharide (degree of polymerization 2). Chitobiose shows hepatoprotective activity and counteracts CCl4-induced elevation of plasma aspartate transaminase and alanine transaminase activities in rats. Chitobiose can be used for the research of carbon tetrachloride-induced acute hepatotoxicity .
    Chitobiose
  • HY-143312
    V-0219

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    V-0219 is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 potentiates GLP-1R stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 potentiates glucose-dependent insulin secretion. V-0219 improves glucose handling in normal and diabetic rodents. V-0219 can be used for the research of obesity-associated diabetes .
    V-0219
  • HY-129963
    3'-UMP disodium

    		Endogenous Metabolite DNA/RNA Synthesis Others
    3'-UMP disodium is a nucleotide, that is a component of ribonucleic acid (RNA) and would be converted to uracil in rat jejunum .
    3'-UMP disodium
  • HY-116930
    S-20928

    		Melatonin Receptor Metabolic Disease
    S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .
    S-20928
  • HY-113316A
    (±)-Salsolinol hydrochloride

    		Endogenous Metabolite Opioid Receptor Neurological Disease
    (±)-Salsolinol hydrochloride is the hydrochloride form of (±)-Salsolinol (HY-113316). (±)-Salsolinol hydrochloride is a Dopamine (HY-B0451)-derived endogenous metabolite. (±)-Salsolinol hydrochloride activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
    (±)-Salsolinol hydrochloride
  • HY-143312A
    V-0219 hydrochloride

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    V-0219 hydrochloride is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 hydrochloride potentiates GLP-1R stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 hydrochloride potentiates glucose-dependent insulin secretion. V-0219 hydrochloride improves glucose handling in normal and diabetic rodents. V-0219 hydrochloride can be used for the research of obesity-associated diabetes .
    V-0219 hydrochloride
  • HY-102065
    SC-19220

    		Prostaglandin Receptor RANKL/RANK Metabolic Disease
    SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .
    SC-19220
  • HY-W039923
    β-D-Galactose pentaacetate

    		Insulin Receptor Endocrinology
    β-D-Galactose pentaacetate is a negative regulator of insulin with plasma membrane penetrating ability and can be hydrolyzed by intracellular esterases. β-D-Galactose pentaacetate inhibits Leucine (HY-N0486)-induced insulin release in Wistar rat islets, potentially preventing excessive insulin release in pathological conditions .
    β-D-Galactose pentaacetate
  • HY-172419
    Blixeprodil

    GM-1020

    		 iGluR Neurological Disease
    Blixeprodil (GM-1020) is the orally active antagonist for NMDA receptor with an affinity of Ki=3.25 µM in rat cortical tissue. Blixeprodil inhibits NR1/2A-NMDAR-mediated currents in HEK293 cell with IC50 of 1.192 µM. Blixeprodil exhibits antidepressant in rats models. Blixeprodil can cross blood-brain barrier .
    Blixeprodil
  • HY-Y0399R
    L-Norvaline (Standard)

    		Amyloid-β Reference Standards TNF Receptor Arginase Neurological Disease Metabolic Disease
    L-Norvaline (Standard) is the analytical standard of L-Norvaline (HY-Y0399). This product is intended for research and analytical applications. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease .
    L-Norvaline (Standard)
  • HY-119671
    BW 755C

    		COX Lipoxygenase Endocrinology
    BW 755C is a 5-lipoxygenase (5-LO) inhibitor with an IC50 of 5 μM. BW 755C also inhibits cyclooxygenase (COX) with IC50s of 0.65 and 1.2 μg/mL against COX-1 and COX-2, respectively .
    BW 755C
  • HY-160602
    CPL207280

    		Free Fatty Acid Receptor Metabolic Disease
    CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
    CPL207280
  • HY-128029
    Glycogen phosphorylase-IN-1

    		Phosphorylase Metabolic Disease
    Glycogen phosphorylase-IN-1 (Compound 42) is an inhibitor for human liver glycogen phosphorylase (hlGPa) and hepatocyte glycogen-derived glucose production with IC50s of 53 and 380 nM, respectively. Glycogen phosphorylase-IN-1 reveals efficacy towards type 2 diabetes .
    Glycogen phosphorylase-IN-1
  • HY-W042193R
    2-Piperidone (Standard)

    δ-Valerolactam (Standard)

    		 Reference Standards Endogenous Metabolite Metabolic Disease
    2-Piperidone is an endogenous metabolite. 2-Piperidone is the biomarker for the activity of CYP2E1 .
    2-Piperidone (Standard)
  • HY-114753
    Neboglamine

    CR-2249; XY-2401

    		 iGluR Neurological Disease
    Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .
    Neboglamine
  • HY-100827
    Safotibant

    LF22-0542

    		 Bradykinin Receptor Inflammation/Immunology
    Safotibant (LF22-0542) is a selective antagonist for kinin B1 receptor (BKB1R), with Ki of 0.35 and 6.5 nM, for human and mouse BKB1R, respectively. Safotibant exhibits analgesic and anti-inflammatory property in mice model .
    Safotibant
  • HY-134521
    Diclofenac amide

    		COX Inflammation/Immunology
    Diclofenac amide is a prodrug for Diclofenac sodium (HY-15037). Diclofenac amide is an orally active inhibitor for COX-1/2, that inhibits the production of prostaglandins (PG) and thromboxanes (TX). Diclofenac amide exhibits anti-inflammatory efficacy in Carrageenan (HY-125474)-induced rat paw edema model without causing gastric ulcer (300 μmol/kg) .
    Diclofenac amide
  • HY-N9515
    Diallyl tetrasulfide

    		Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    Diallyl tetrasulfide is an orally active diallyl tetrasulfide. Diallyl tetrasulfide ameliorates cadmium-induced changes in acetylcholinesterase and adenosine triphosphatase activities as well as oxidative stress injury in the brain of rats . Diallyl tetrasulfide inhibits lipid peroxidation in rat liver microsomes . Diallyl tetrasulfide ameliorates cadmium-induced oxidative liver injury in rats . Diallyl tetrasulfide protects cells against cadmium-induced loss of cell viability, reduces apoptosis rate and ROS production. Diallyl tetrasulfide is applicable to research related to cadmium-induced neurotoxicity and cadmium-induced oxidative liver injury .
    Diallyl tetrasulfide
  • HY-161618
    MJ04

    		JAK EGFR PI3K IGF-1R GSK-3 Inflammation/Immunology Endocrinology
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg) .
    MJ04
  • HY-105088A
    Pexiganan acetate

    MSI 78

    		 Bacterial Infection
    Pexiganan (MSI 78) acetate is an orally active antimicrobial peptide with broad-spectrum bactericidal. Pexiganan TFA disrupts bacterial cell membranes, induces peptidoglycan damage and cell lysis. Pexiganan acetate can be used for the research of bacterial infection .
    Pexiganan acetate
  • HY-N9737
    (−)-Acutumine

    		Others Neurological Disease
    (−)-Acutumine is a tetracyclic chloroalkaloid that exhibits selective cytotoxicity to cultured human T cells and memory-enhancing properties in the Wistar rat model .
    (−)-Acutumine
  • HY-169404
    PPARγ agonist 15

    		PPAR Metabolic Disease
    PPARγ agonist 15 (Compound 7c) is an agonist for PPARγ. PPARγ agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC50 of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model .
    PPARγ agonist 15
  • HY-120329
    Lu 26-046

    		mAChR Others
    Lu 26-046 is the agonist for muscarinic M1 receptor and M2 receptor and a weak antagonist for M3 receptor, with Ki of 0.51, 26 and 5 nM, respectively. Lu 26-046 exhibits specific stimulus property, that can be recognized by rats .
    Lu 26-046
  • HY-W783623
    1,3-Didocosahexaenoyl glycerol

    DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin

    		 Biochemical Assay Reagents Cardiovascular Disease
    1,3-Didocosahexaenoyl glycerol (DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin) is an ω-3 polyunsaturated fatty acid, which exhibits cardioprotective effects in rat myocardial ischemia/reperfusion (I/R) injury model through conjugation with Poly-l-glutamic acid (PGA) .
    1,3-Didocosahexaenoyl glycerol
  • HY-119750
    Budralazine

    		Adrenergic Receptor Cardiovascular Disease
    Budralazine is a vasodilator, which dilates the vascular smooth muscle and exhibits hypotensive efficacy. Budralazine inhibits the central sympathetic nerve and exhibits an anti-tachycardic effect .
    Budralazine
  • HY-164011
    Alaproclate

    		5-HT Receptor Neurological Disease
    Alaproclate is an inhibitor for serotonin (5-HT) reuptake. Alaproclate affects mechanisms that related to cued navigation performance such as sensory, sensorimotor, or motivational factors, impairs spatial navigation ability of rats .
    Alaproclate
  • HY-19126
    CL-184005

    		Platelet-activating Factor Receptor (PAFR) Infection Cardiovascular Disease
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
    CL-184005
  • HY-161896
    Transcription factor-IN-1

    		GABA Receptor Neurological Disease
    Transcription factor-IN-1 (Compound 4e) is an inhibitor for transcription factor. Transcription factor-IN-1 exhibits anticonvulsant activity by antagonism with pentylenetetrazole (PTZ) (ED50 =34.5 mg/kg). Transcription factor-IN-1 exhibits antidepressant effects in rat models .
    Transcription factor-IN-1
  • HY-W587489
    RL-603

    		Drug Metabolite Cardiovascular Disease
    RL-603 is the metabolite of Anagrelide (HY-B0523). RL-603 exhibits platelet-lowering activity in mouse model .
    RL-603
  • HY-W013353
    (RS)-Salsolinol hydrobromide

    		Endogenous Metabolite Opioid Receptor Neurological Disease
    (RS)-Salsolinol hydrobromide is the hydrobromide form of (±)-Salsolinol (HY-113316). (RS)-Salsolinol hydrobromide is a Dopamine (HY-B0451)-derived endogenous metabolite. (RS)-Salsolinol hydrobromide activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
    (RS)-Salsolinol hydrobromide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: